Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease

Background. Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronically remittent and progressive inflammatory disorders. Phospholipase D2 (PLD2) is reported to be involved in the pathogenesis of several inflammatory diseases. However, the exact rol...

Full description

Saved in:
Bibliographic Details
Main Authors: Guangxi Zhou, Lin Yu, Wenjing Yang, Wei Wu, Leilei Fang, Zhanju Liu
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2016/2543070
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560592379969536
author Guangxi Zhou
Lin Yu
Wenjing Yang
Wei Wu
Leilei Fang
Zhanju Liu
author_facet Guangxi Zhou
Lin Yu
Wenjing Yang
Wei Wu
Leilei Fang
Zhanju Liu
author_sort Guangxi Zhou
collection DOAJ
description Background. Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronically remittent and progressive inflammatory disorders. Phospholipase D2 (PLD2) is reported to be involved in the pathogenesis of several inflammatory diseases. However, the exact role of PLD2 in IBD is obscure. Methods. PLD2 expression was determined in peripheral blood cells and inflamed mucosa from patients with IBD by qRT-PCR. Colonic biopsies were also obtained from CD patients before and after infliximab (IFX) treatment to examine PLD2 expression. PLD2 selective inhibitor (CAY10594) was administrated daily by oral gavage in DSS-induced colitis mice. Bone marrow neutrophils from colitis mice were harvested to examine the migration using Transwell plate. Results. PLD2 was found to be significantly increased in peripheral blood cells and inflamed mucosa in patients with active IBD. Treatment with IFX could significantly decrease PLD2 expression in intestinal mucosa in patients with CD. Moreover, blockade of PLD2 with CAY10594 could markedly ameliorate DSS-induced colitis in mice and promote neutrophil migration. Conclusions. PLD2 plays a critical role in the pathogenesis of IBD. Blockade of PLD2 may serve as a new therapeutic approach for treatment of IBD.
format Article
id doaj-art-455677ca95584ee2bd4bef9ceb0724ed
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-455677ca95584ee2bd4bef9ceb0724ed2025-02-03T01:27:13ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/25430702543070Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel DiseaseGuangxi Zhou0Lin Yu1Wenjing Yang2Wei Wu3Leilei Fang4Zhanju Liu5Department of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaDepartment of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaDepartment of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaDepartment of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaDepartment of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaDepartment of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaBackground. Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronically remittent and progressive inflammatory disorders. Phospholipase D2 (PLD2) is reported to be involved in the pathogenesis of several inflammatory diseases. However, the exact role of PLD2 in IBD is obscure. Methods. PLD2 expression was determined in peripheral blood cells and inflamed mucosa from patients with IBD by qRT-PCR. Colonic biopsies were also obtained from CD patients before and after infliximab (IFX) treatment to examine PLD2 expression. PLD2 selective inhibitor (CAY10594) was administrated daily by oral gavage in DSS-induced colitis mice. Bone marrow neutrophils from colitis mice were harvested to examine the migration using Transwell plate. Results. PLD2 was found to be significantly increased in peripheral blood cells and inflamed mucosa in patients with active IBD. Treatment with IFX could significantly decrease PLD2 expression in intestinal mucosa in patients with CD. Moreover, blockade of PLD2 with CAY10594 could markedly ameliorate DSS-induced colitis in mice and promote neutrophil migration. Conclusions. PLD2 plays a critical role in the pathogenesis of IBD. Blockade of PLD2 may serve as a new therapeutic approach for treatment of IBD.http://dx.doi.org/10.1155/2016/2543070
spellingShingle Guangxi Zhou
Lin Yu
Wenjing Yang
Wei Wu
Leilei Fang
Zhanju Liu
Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease
Mediators of Inflammation
title Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease
title_full Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease
title_fullStr Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease
title_full_unstemmed Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease
title_short Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease
title_sort blockade of pld2 ameliorates intestinal mucosal inflammation of inflammatory bowel disease
url http://dx.doi.org/10.1155/2016/2543070
work_keys_str_mv AT guangxizhou blockadeofpld2amelioratesintestinalmucosalinflammationofinflammatoryboweldisease
AT linyu blockadeofpld2amelioratesintestinalmucosalinflammationofinflammatoryboweldisease
AT wenjingyang blockadeofpld2amelioratesintestinalmucosalinflammationofinflammatoryboweldisease
AT weiwu blockadeofpld2amelioratesintestinalmucosalinflammationofinflammatoryboweldisease
AT leileifang blockadeofpld2amelioratesintestinalmucosalinflammationofinflammatoryboweldisease
AT zhanjuliu blockadeofpld2amelioratesintestinalmucosalinflammationofinflammatoryboweldisease